Alcon’s Travatan Ad Comparisons To Xalatan, Lumigan Are Misleading, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Division of Drug Marketing, Advertising & Communications cites a Travatan promotional card for unsubstantiated comparison claims in an "untitled" letter.
You may also be interested in...
Alcon Gets Third FDA Warning On Sales Claims For Eye And Ear Drugs
Nevanac joins Cipro HC Otic and Travaton in being cited by the agency’s advertising division.
Alcon Gets Third FDA Warning On Sales Claims For Eye And Ear Drugs
Nevanac joins Cipro HC Otic and Travaton in being cited by the agency’s advertising division.
Allergan Lumigan Unsubstantiated Superiority Claims Cited In FDA Warning Letter
The company must send corrective messages regarding the violative sales aid for Lumigan that contains misleading claims regarding the superiority of the ocular therapy, FDA says.